Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

3.3K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

820
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
820
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

807
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
807
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

425
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
425
Long-term Potentiation01:25

Long-term Potentiation

3.2K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
3.2K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.4K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developing evidence-informed pathways for long-term engagement in cycling for the United States.

Frontiers in sports and active living·2026
Same author

A scoping review of bicycling interventions' impacts on psychological, social, affective, and cognitive well-being.

Frontiers in sports and active living·2026
Same author

Psychosocial well-being in middle schoolers: effects of a school cycling program in the wake of COVID-19.

Frontiers in sports and active living·2025
Same author

Return to Sport and Performance Outcomes After Hand Fractures in Professional Baseball Players.

Orthopaedic journal of sports medicine·2025
Same author

Surgical Approach to Acute Osteochondral Fracture With Patellar Instability in Skeletally Immature Patients.

Video journal of sports medicine·2025
Same author

Evaluating a novel team learning approach for integrating drugs in sports education in preclinical medical training.

Frontiers in medicine·2025

Related Experiment Video

Updated: Dec 12, 2025

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
18:01

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

14.5K

Classics in Chemical Neuroscience: Pramipexole.

Sean M Wilson1, Madeline G Wurst1, Michael F Whatley1

  • 1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Lipscomb University, Nashville, Tennessee 37204, United States.

ACS Chemical Neuroscience
|August 14, 2020
PubMed
Summary

Pramipexole, a dopamine D2-like receptor agonist, is effective for Parkinson's disease and restless leg syndrome. Its D3-preferring properties offer therapeutic potential for motor and psychiatric symptoms.

Keywords:
DepressionDopamine agonistMirapexParkinson’s diseasePramipexoleRestless leg syndrome

More Related Videos

Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior
10:05

Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior

Published on: September 16, 2015

14.8K
Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats
09:43

Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats

Published on: October 5, 2021

2.8K

Related Experiment Videos

Last Updated: Dec 12, 2025

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
18:01

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

14.5K
Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior
10:05

Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior

Published on: September 16, 2015

14.8K
Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats
09:43

Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats

Published on: October 5, 2021

2.8K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Pramipexole is a nonergoline aminobenzothiazole compound.
  • It selectively agonizes dopamine D2-like receptors (D2, D3, D4).
  • Pramipexole exhibits D3 receptor-preferring properties.

Purpose of the Study:

  • To review the synthesis, metabolism, pharmacology, and adverse effects of pramipexole.
  • To discuss the therapeutic role of pramipexole in neurological and psychiatric disorders.
  • To highlight the importance of pramipexole in neuroscience.

Main Methods:

  • Literature review of pramipexole's properties and applications.
  • Analysis of pramipexole's mechanism of action on dopamine receptors.
  • Examination of clinical uses in Parkinson's disease and restless leg syndrome.

Main Results:

  • Pramipexole is approved for Parkinson's disease and restless leg syndrome.
  • Its D3 receptor affinity suggests potential for psychiatric symptoms.
  • The drug's synthesis, metabolism, and adverse effects are detailed.

Conclusions:

  • Pramipexole is a significant therapeutic agent targeting dopamine D2-like receptors.
  • Its unique D3-preferring action has implications for motor and psychiatric conditions.
  • This review provides a comprehensive overview of pramipexole's role in neuroscience and therapy.